CO6541545A2 - Compuestos de espiropiperidina como antagonistas del receptor orl-1 - Google Patents

Compuestos de espiropiperidina como antagonistas del receptor orl-1

Info

Publication number
CO6541545A2
CO6541545A2 CO12073055A CO12073055A CO6541545A2 CO 6541545 A2 CO6541545 A2 CO 6541545A2 CO 12073055 A CO12073055 A CO 12073055A CO 12073055 A CO12073055 A CO 12073055A CO 6541545 A2 CO6541545 A2 CO 6541545A2
Authority
CO
Colombia
Prior art keywords
orl
compounds
spyropiperidine
antrogonists
receiver
Prior art date
Application number
CO12073055A
Other languages
English (en)
Spanish (es)
Inventor
Collado Ana Belen Benito
Buezo Nuria Diaz
Escribano Miguel Angel Toledo
Concepcion Pedregal-Tercero
Grau Maria Angeles Martinez
Blanco Celia Lafuente
Aguado Alma Maria Jimenz
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CO6541545A2 publication Critical patent/CO6541545A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/20Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CO12073055A 2009-11-16 2012-05-04 Compuestos de espiropiperidina como antagonistas del receptor orl-1 CO6541545A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09382246 2009-11-16
US29862910P 2010-01-27 2010-01-27

Publications (1)

Publication Number Publication Date
CO6541545A2 true CO6541545A2 (es) 2012-10-16

Family

ID=41728051

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12073055A CO6541545A2 (es) 2009-11-16 2012-05-04 Compuestos de espiropiperidina como antagonistas del receptor orl-1

Country Status (34)

Country Link
US (1) US8232289B2 (OSRAM)
EP (1) EP2501703B1 (OSRAM)
JP (1) JP5680101B2 (OSRAM)
KR (1) KR101363830B1 (OSRAM)
CN (1) CN102612520B (OSRAM)
AR (1) AR078863A1 (OSRAM)
AU (1) AU2010319581C1 (OSRAM)
CA (1) CA2796161C (OSRAM)
CO (1) CO6541545A2 (OSRAM)
CR (1) CR20130087A (OSRAM)
DK (1) DK2501703T3 (OSRAM)
DO (1) DOP2012000135A (OSRAM)
EA (1) EA020848B1 (OSRAM)
EC (1) ECSP12011902A (OSRAM)
ES (1) ES2435814T3 (OSRAM)
HN (1) HN2012001011A (OSRAM)
HR (1) HRP20130967T1 (OSRAM)
IL (1) IL219370A (OSRAM)
JO (1) JO2887B1 (OSRAM)
MA (1) MA33751B1 (OSRAM)
ME (1) ME01537B (OSRAM)
MX (1) MX2012005691A (OSRAM)
MY (1) MY160665A (OSRAM)
NZ (1) NZ600006A (OSRAM)
PE (1) PE20121430A1 (OSRAM)
PH (1) PH12012500969A1 (OSRAM)
PL (1) PL2501703T3 (OSRAM)
PT (1) PT2501703E (OSRAM)
RS (1) RS53018B (OSRAM)
SI (1) SI2501703T1 (OSRAM)
TW (1) TWI465453B (OSRAM)
UA (1) UA107943C2 (OSRAM)
WO (1) WO2011060035A1 (OSRAM)
ZA (1) ZA201202967B (OSRAM)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ767139A (en) 2009-12-04 2022-08-26 Sunovion Pharmaceuticals Inc Multicyclic compounds and methods of use thereof
JP2013540145A (ja) * 2010-10-21 2013-10-31 ウニベルシテート デス ザールランデス コルチゾール依存性疾患の治療用の選択的cyp11b1阻害剤
TWI582096B (zh) * 2011-12-06 2017-05-11 美國禮來大藥廠 用於酒精依賴及濫用處理之4',5'-二氫螺[哌啶-4,7'-噻吩并[2,3-c]哌喃]化合物
TW201416370A (zh) 2012-07-31 2014-05-01 Lilly Co Eli 用於治療焦慮之orl-1受體拮抗劑
WO2014053450A1 (de) 2012-10-02 2014-04-10 Bayer Cropscience Ag Heterocyclische verbindungen als schädlingsbekämpfungsmittel
EP2919788A4 (en) 2012-11-14 2016-05-25 Univ Johns Hopkins METHOD AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA
TW201607923A (zh) 2014-07-15 2016-03-01 歌林達有限公司 被取代之氮螺環(4.5)癸烷衍生物
JO3638B1 (ar) * 2015-09-09 2020-08-27 Lilly Co Eli مركبات مفيدة في تثبيط ror - جاما- t
KR20190065246A (ko) 2016-07-29 2019-06-11 선오비온 파마슈티컬스 인코포레이티드 화합물 및 조성물 및 이들의 용도
US10196403B2 (en) 2016-07-29 2019-02-05 Sunovion Pharmaceuticals Inc. Compounds and compositions and uses thereof
WO2018151861A1 (en) 2017-02-16 2018-08-23 Sunovion Pharamaceuticials Inc. Methods of treating schizophrenia
PL3589638T3 (pl) 2017-03-02 2021-09-27 Eli Lilly And Company Związki użyteczne do hamowania ror-gamma-t
EP3589637B1 (en) * 2017-03-02 2021-04-14 Eli Lilly and Company Compounds useful for inhibiting ror-gamma-t
JP7191085B2 (ja) 2017-08-02 2022-12-16 サノビオン ファーマシューティカルズ インク イソクロマン化合物およびその使用
EP3752508A1 (en) 2018-02-16 2020-12-23 Sunovion Pharmaceuticals Inc. Salts, crystal forms, and production methods thereof
US11618746B2 (en) 2018-12-17 2023-04-04 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
MX2021010880A (es) 2019-03-14 2022-01-18 Sunovion Pharmaceuticals Inc Sales de un compuesto de isocromanilo y formas cristalinas, procesos de preparacion, usos terapeuticos y composiciones farmaceuticas de las mismas.
WO2021211489A1 (en) 2020-04-14 2021-10-21 Sunovion Pharmaceuticals Inc. (s)-(4,5-dihydro-7h-thieno[2,3-c]pyran-7-yl)-n-methylmethanamine for treating neurological and psychiatric disorders
AR123355A1 (es) 2020-08-26 2022-11-23 Vertex Pharma Inhibidores de apol1 y métodos para usar los mismos
US20250171459A1 (en) * 2022-02-08 2025-05-29 Vertex Pharmaceuticals Incorporated 2-methyl-4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran] derivatives as inhibitors of apol1 and methods of using same

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL96507A0 (en) 1989-12-08 1991-08-16 Merck & Co Inc Nitrogen-containing spirocycles and pharmaceutical compositions containing them
AU1948601A (en) 1999-12-06 2001-06-12 Euro-Celtique S.A. Triazospiro compounds having nociceptin receptor affinity
ATE403429T1 (de) 2001-04-18 2008-08-15 Euro Celtique Sa Spiropyrazol-verbindungen
WO2002088089A1 (en) 2001-04-19 2002-11-07 Banyu Pharmaceutical Co., Ltd. Spiropiperidine derivatives, nociceptin receptor antagonists containing the same as the active ingredient and medicinal compositions
ATE396995T1 (de) 2001-07-23 2008-06-15 Banyu Pharma Co Ltd 4-oxoimidazolidin-2-spiro piperidin derivat
JP2005519921A (ja) * 2002-01-28 2005-07-07 ファイザー株式会社 Orl−1受容体リガンドとしてのn置換スピロピペリジン化合物
JPWO2003095427A1 (ja) 2002-05-10 2005-09-15 大正製薬株式会社 スピロ環化合物
US6995168B2 (en) 2002-05-31 2006-02-07 Euro-Celtique S.A. Triazaspiro compounds useful for treating or preventing pain
MXPA05002622A (es) 2002-09-09 2005-09-08 Johnson & Johnson Derivados de 1,3,8,-triazaespiro [4.5]decan-4-ona sustituidos con hidroxialquilo utiles para el tratamiento de desordenes mediados por el receptor opioide huerfano.
WO2005016913A1 (en) * 2003-08-19 2005-02-24 Pfizer Japan, Inc. Tetrahydroisoquinoline or isochroman compounds as orl-1 receptor ligands for the treatment of pain and cns disorders
DE10360792A1 (de) * 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
BRPI0509307A (pt) * 2004-03-29 2007-09-04 Pfizer compostos de alfa aril ou heteroaril metil beta piperidino propanamida como antagonistas do receptor orl1
DE102004039382A1 (de) * 2004-08-13 2006-02-23 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
EP2020414A1 (en) 2007-06-20 2009-02-04 Laboratorios del Dr. Esteve S.A. spiro[piperidine-4,4'-thieno[3,2-c]pyran] derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis
PT2260042E (pt) 2008-03-27 2011-12-06 Gruenenthal Gmbh Derivados de ciclo-hexano espirocíclicos substituídos

Also Published As

Publication number Publication date
MY160665A (en) 2017-03-15
RS53018B (sr) 2014-04-30
EP2501703B1 (en) 2013-09-18
CA2796161A1 (en) 2011-05-19
NZ600006A (en) 2014-05-30
PL2501703T3 (pl) 2014-02-28
ME01537B (me) 2014-04-20
CN102612520A (zh) 2012-07-25
MA33751B1 (fr) 2012-11-01
TWI465453B (zh) 2014-12-21
ZA201202967B (en) 2013-09-25
HK1169988A1 (en) 2013-02-15
DK2501703T3 (da) 2013-10-14
PE20121430A1 (es) 2012-10-26
DOP2012000135A (es) 2012-08-15
CN102612520B (zh) 2015-04-08
KR101363830B1 (ko) 2014-02-14
IL219370A0 (en) 2012-06-28
CA2796161C (en) 2015-03-17
JP2013510859A (ja) 2013-03-28
US8232289B2 (en) 2012-07-31
UA107943C2 (xx) 2015-03-10
EP2501703A1 (en) 2012-09-26
MX2012005691A (es) 2012-06-13
EA201290352A1 (ru) 2012-10-30
SI2501703T1 (sl) 2013-11-29
AU2010319581C1 (en) 2014-05-15
CR20130087A (es) 2013-04-17
EA020848B1 (ru) 2015-02-27
IL219370A (en) 2015-01-29
KR20130026523A (ko) 2013-03-13
HRP20130967T1 (hr) 2013-11-22
WO2011060035A1 (en) 2011-05-19
PH12012500969A1 (en) 2013-01-07
PT2501703E (pt) 2013-11-26
ES2435814T3 (es) 2013-12-23
AU2010319581B2 (en) 2013-12-19
US20110118251A1 (en) 2011-05-19
AU2010319581A1 (en) 2012-06-07
TW201127841A (en) 2011-08-16
HN2012001011A (es) 2015-08-31
JP5680101B2 (ja) 2015-03-04
JO2887B1 (en) 2015-03-15
ECSP12011902A (es) 2012-07-31
AR078863A1 (es) 2011-12-07

Similar Documents

Publication Publication Date Title
CO6541545A2 (es) Compuestos de espiropiperidina como antagonistas del receptor orl-1
NI201300043A (es) Antagonistas del receptor del cgrp de piperidinona carboxamida azaindano
GT200900231A (es) Moduladores 2-aminopirimidina del receptor de histamina h4
CO6480918A2 (es) Antagonistas policíclicos de receptores de ácido lisofosfatídico.
MX342161B (es) Compuestos antagonistas selectivos de receptor nk-3 novedosos, composicion farmaceutica y metodos para utilizarse en trastornos transmitidos por receptores nk-3.
EA201290296A1 (ru) Циклические пептиды, специфичные к рецептору меланокортина-1
DOP2014000115A (es) Uso de 4-fenil-piridinas sustituidas para la fabricación de medicamentos útiles en el tratamiento de enfermedades relacionadas con el receptor de nk1
CR11751A (es) Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta3
PH12015501289A1 (en) Novel benzimidazole derivatives as ep4 antagonists
CR20110509A (es) Composicion farmaceutica
SMT201600055B (it) Composizione farmaceutica per il trattamento o la prevenzione del glaucoma
CO6771417A2 (es) Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis
DK3061821T3 (da) Sammensætninger til behandling af forstyrrelser lindret af muskarinreceptoraktivering
MX339899B (es) Compuestos de triazolopiridina como inhibidores de pim cinasa.
BR112012007747B8 (pt) compostos heterocíclicos úteis como inibidores de pdk1, sua composição farmacêutica e seus usos
ECSP13012900A (es) Novedosos derivados de azabencimidazol cíclico útiles como agentes antidiabéticos
UY32574A (es) Antagonistas del receptor cxcr3
CO6781501A2 (es) Dihidrofuranos condensados en calidad de modulares de gpr119 para el tratamiento de diabetes, obesidad y trastornos relacionados
EA201100161A1 (ru) Производные хинуклидина карбоната и их медицинские композиции
CL2013002412A1 (es) Compuestos derivados de (piperidin-4-il)-ureas; composicion farmaceutica; y uso como antagonistas del receptor grelina en el tratamiento de la obesidad, trastornos alimenticios, diabetes, caquexia causada por el cancer, insuficiencia cardiaca congestiva, entre otras.
MX2013012652A (es) Derivados de n-[(1h-pirazol-1-il)aril]-1h-indol o 1h-indazol-3-carboxamida, su preparacion y su uso como antagonistas p2y12.
EA201391618A1 (ru) Комбинация, содержащая умеклидиний и кортикостероид
CR11600A (es) Derivados de indazol
EA201400623A1 (ru) Новые 2h-индазолы в качестве антагонистов рецептора ep
UY31840A (es) Pirrolidin amidas sustituidas como moduladores del receptor histamina h3

Legal Events

Date Code Title Description
FG Application granted